Pharma BD Deal Intelligence
AbbVie's ~$5.8-9.8B bet on Rova-T collapsed entirely — three failed Phase 3 trials, ~$5B in impairment charges, program terminated in 2019, zero commercial return.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
GEN reported the up-to-$9.8B Stemcentrx acquisition framed as AbbVie's bet on Rova-T and the Stemcentrx cancer stem cell discovery platform; many analysts felt…
FierceBiotech: AbbVie takes a $4B impairment on Rova-T failures, validating earlier skepticism that paying $5.8B upfront for an unproven late-stage ADC was…
Pharmaphorum's retrospective: Rova-T became a textbook case of a 'multi-billion dollar failure' — overpriced biotech M&A, Phase 1/2 data over-extrapolated, and…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
AbbVie acquired South San Francisco-based Stemcentrx for ~$5.8B (approximately $2B cash + $3.8B AbbVie stock) plus up to $4B in success-based milestones (~$9.8B total). Lead asset Rova-T was an anti-DLL3 ADC in registrational trials for SCLC. Acquisition recorded $4B impairment in 2018-2020 after Phase 3 failures; program ultimately terminated.
AbbVie's ~$5.8-9.8B bet on Rova-T collapsed entirely — three failed Phase 3 trials, ~$5B in impairment charges, program terminated in 2019, zero commercial return.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Stemcentrx Inc. (this deal) | 2016 | $9.8B | 9 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2016 deals · AbbVie Inc. deals · Oncology deals